Skip to content

US · BDTX · BIOTECHNOLOGY

Black Diamond Therapeutics, Inc. (BDTX) intrinsic value and stock valuation

$1.31as of 2026-11-21 · Mkt cap 102.57M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Black Diamond Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values BDTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BDTX’s statements →

Black Diamond Therapeutics, Inc. Graham Number

Graham Number: $4.18d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02142 blackdiamondtherapeutics.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$70M
20172025
Net income
$22.4M
20172025
Free cash flow
$29.6M
20172025
Total equity
$112.2M-18.3% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$70M$0.00$0.00$0.00$0.00
Operating income$19.9M-$-78.78M-$-86.46M-$-92.83M-$-126.87M
Net income$22.4M-$-69.68M-$-82.44M-$-91.17M-$-125.6M
EPSd$388.6K-$-1.27M-$-1.88M-$-2.52M-$-3.47M
Operating cash flow$29.6M-$-62.3M-$-66.72M-$-85.08M-$-100.15M
Capital expenditure$0.00$0.00-$-30K-$-190K-$-2.71M
Free cash flow$29.6M-$-62.3M-$-66.75M-$-85.27M-$-102.86M
Total assets$143M$122.6M$158.6M$156.3M$247.7M
Total debt$18.8M$22.2M$25.3M$28.1M$28.5M
Net debt-$-2.21M-$-14.25M-$-30.92M-$-6.17M-$-37.34M
Total equity$112.2M$83.3M$116.7M$115.7M$195.9M
Cash and short-term investments$128.7M$98.6M$131.4M$122.8M$209.8M
Income statement
20252024202320222021
Revenue$70M$0.00$0.00$0.00$0.00
Cost of revenue$330K$0.00$440K$0.00$0.00
Gross profit$69.7M$0.00-$-440K$0.00$0.00
Research and development expenses$33.6M$51.3M$58.9M$64.4M$96.8M
Selling, general and administrative expenses$16.6M$27.5M$27.1M$28.4M$30M
Other expenses-$-330K$0.00$0.00$0.00$0.00
Operating expenses$49.8M$78.8M$86M$92.8M$126.9M
Cost and expenses$50.1M$78.8M$86.5M$92.8M$126.9M
Interest income$4.06M$2.18M$1.92M$2.03M$3.46M
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$330K$340K$440K$510K$200K
Ebitda$22.7M-$-69.33M-$-82M-$-90.66M-$-125.39M
Operating income$19.9M-$-78.78M-$-86.46M-$-92.83M-$-126.87M
Total other income/expenses, net$2.5M$9.11M$4.02M$1.66M$1.28M
Income before tax$22.4M-$-69.68M-$-82.44M-$-91.17M-$-125.6M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income$22.4M-$-69.68M-$-82.44M-$-91.17M-$-125.6M
Weighted average shares outstanding$56.9M$55M$44M$36.2M$36.2M
Weighted average diluted shares outstanding$57.6M$55M$44M$36.2M$36.2M
Balance sheet
20252024202320222021
Cash and short-term investments$128.7M$98.6M$131.4M$122.8M$209.8M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$132.4M$101.2M$134M$127.7M$215.7M
Property, plant and equipment, net$9.67M$20.4M$23.7M$27.4M$30.7M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$830K$0.00$0.00$0.00$0.00
Total non-current assets$10.6M$21.5M$24.5M$28.6M$32M
Total assets$143M$122.6M$158.6M$156.3M$247.7M
Accounts payable$580K$4.01M$2.32M$1.88M$4.11M
Short-term debt$3.71M$3.4M$3.11M$2.84M$320K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$15.7M$20.6M$19.7M$15.3M$23.6M
Long-term debt$15.1M$18.8M$22.2M$25.3M$28.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$15.1M$18.8M$22.2M$25.3M$28.1M
Capital lease obligations$18.8M$22.2M$25.3M$28.1M$28.5M
Total liabilities$30.8M$39.4M$41.8M$40.6M$51.8M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-464.74M-$-487.11M-$-417.43M-$-334.99M-$-243.82M
Accumulated other comprehensive income (loss)$100K$20K-$-30K-$-1.82M-$-410K
Total equity$112.2M$83.3M$116.7M$115.7M$195.9M
Total investments$108.5M$62.1M$75.2M$88.5M$144M
Total debt$18.8M$22.2M$25.3M$28.1M$28.5M
Net debt-$-2.21M-$-14.25M-$-30.92M-$-6.17M-$-37.34M
Cash flow statement
20252024202320222021
Net income$22.4M-$-69.68M-$-82.44M-$-91.17M-$-125.6M
Depreciation and amortization$330K$340K$440K$510K$200K
Stock-based compensation$6.63M$10.6M$9.6M$12.2M$14M
Change in working capital-$-8.73M-$-2.69M$3.69M-$-9.9M$7.02M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-3.43M$1.68M$600K-$-2.23M$1.57M
Net cash provided by operating activities$29.6M-$-62.3M-$-66.72M-$-85.08M-$-100.15M
Investments in property, plant and equipment$0.00$0.00-$-30K-$-190K-$-2.71M
Acquisitions, net$30K$90K$0.00$10K$2.7M
Net cash used for investing activities-$-44.91M$17M$16.4M$53.4M$130.6M
Common stock issued-$-150K$24.5M$71.9M$180K$730K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-150K$25.6M$71.9M$180K$730K
Net change in cash-$-15.44M-$-19.79M$21.6M-$-31.54M$31.2M
Cash at end of period$21.8M$37.3M$57M$35.5M$67M
Operating cash flow$29.6M-$-62.3M-$-66.72M-$-85.08M-$-100.15M
Capital expenditure$0.00$0.00-$-30K-$-190K-$-2.71M
Free cash flow$29.6M-$-62.3M-$-66.75M-$-85.27M-$-102.86M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Black Diamond Therapeutics, Inc.

        Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.

        CEO
        Mark A. Velleca
        Employees
        21
        Beta
        3.25

        Explore

        Frequently asked questions

        What is the intrinsic value of Black Diamond Therapeutics, Inc. (BDTX)?

        InvestorsCraft does not currently publish an intrinsic value for BDTX. How the IC value is calculated.

        Is BDTX undervalued?

        InvestorsCraft does not publish an undervaluation signal for BDTX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.